Prevalence and Clinical Associations of CXCR4-Using HIV-1 Among Treatment-Naive Subtype C-Infected Women in Botswana

HIV-1 coreceptor use was determined using a phenotypic assay in plasma samples from treatment-naive women infected with subtype C virus who had CD4 cell counts below 200 cells/mm3. Of 148 women, 14.9% were infected with dual/mixed virus; the remainder had R5 virus. A greater proportion of women in the lowest CD4 cell count stratum had dual/mixed virus (P = 0.026); change in coreceptor use after antiretroviral therapy exposure was uncommon. CXCR4-using HIV-1 was less common in subtype C-infected women than reported in subtype B cohorts but was most prevalent in women with the lowest CD4 cell counts.

[1]  R. Beroukhim,et al.  The design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates. , 2010, Journal of virological methods.

[2]  M. Hughes,et al.  Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. , 2009, The Journal of infectious diseases.

[3]  Paolo Piazza,et al.  Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study. , 2008, The Journal of infectious diseases.

[4]  Bernard Hirschel,et al.  Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. , 2008, The New England journal of medicine.

[5]  A. Capovilla,et al.  Genotypic characterization and comparison of full-length envelope glycoproteins from South African HIV type 1 subtype C primary isolates that utilize CCR5 and/or CXCR4. , 2008, AIDS research and human retroviruses.

[6]  A. Capovilla,et al.  Emergence of X4 usage among HIV-1 subtype C: evidence for an evolving epidemic in South Africa , 2008, AIDS.

[7]  S. Lagakos,et al.  Response to antiretroviral therapy after a single, peripartum dose of nevirapine. , 2007, The New England journal of medicine.

[8]  J. Mullins,et al.  Prevalence and genetic diversity of HIV type 1 subtypes A and D in women attending antenatal clinics in Uganda. , 2007, AIDS research and human retroviruses.

[9]  P. Kaleebu,et al.  Relation Between Chemokine Receptor Use, Disease Stage, and HIV-1 Subtypes A and D: Results From a Rural Ugandan Cohort , 2007, Journal of acquired immune deficiency syndromes.

[10]  Eoin Coakley,et al.  HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  L. Ping,et al.  Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. , 2006, Virology.

[12]  David W. Williamson,et al.  Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. , 2006, The Journal of infectious diseases.

[13]  Peter B Gilbert,et al.  Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. , 2006, JAMA.

[14]  N. Graham,et al.  HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. , 2006, The Journal of infectious diseases.

[15]  S. Lagakos,et al.  Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana , 2006, AIDS.

[16]  L. Morris,et al.  Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progression. , 2006, AIDS research and human retroviruses.

[17]  T. Ndung’u,et al.  HIV-1 subtype C in vitro growth and coreceptor utilization. , 2006, Virology.

[18]  P. Harrigan,et al.  Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. , 2005, The Journal of infectious diseases.

[19]  Christophe Pasquier,et al.  R5 to X4 Switch of the Predominant HIV-1 Population in Cellular Reservoirs During Effective Highly Active Antiretroviral Therapy , 2005, Journal of acquired immune deficiency syndromes.

[20]  B. Gazzard,et al.  Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. , 2005, The Journal of infectious diseases.

[21]  Rami Kantor,et al.  High Frequency of Syncytium-Inducing and CXCR4-Tropic Viruses among Human Immunodeficiency Virus Type 1 Subtype C-Infected Patients Receiving Antiretroviral Treatment , 2003, Journal of Virology.

[22]  Lynn Morris,et al.  The CCR5 and CXCR4 Coreceptors Are Both Used by Human Immunodeficiency Virus Type 1 Primary Isolates from Subtype C , 2003, Journal of Virology.

[23]  S. Engelbrecht,et al.  Change in co-receptor usage of current South African HIV-1 subtype C primary isolates. , 2002, AIDS.

[24]  W. Dowling,et al.  Full-length genome analysis of HIV-1 subtype C utilizing CXCR4 and intersubtype recombinants isolated in South Africa. , 2002, AIDS research and human retroviruses.

[25]  R. Paranjape,et al.  Absence of coreceptor switch with disease progression in human immunodeficiency virus infections in India. , 2000, Virology.

[26]  P. Vernazza,et al.  Characterization of V3 Sequence Heterogeneity in Subtype C Human Immunodeficiency Virus Type 1 Isolates from Malawi: Underrepresentation of X4 Variants , 1999, Journal of Virology.

[27]  T. F. Rinke de Wit,et al.  HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. , 1999, AIDS.

[28]  J. Albert,et al.  Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. , 1999, AIDS research and human retroviruses.

[29]  D. Katzenstein,et al.  Primary subtype C HIV-1 infection in Harare, Zimbabwe. , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[30]  H. Furrer,et al.  Association of syncytium‐inducing phenotype of HIV‐1 with CD4 cell count, viral load and sociodemographic characteristics , 1998, AIDS (London).

[31]  R. Connor,et al.  Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.

[32]  D. Richman,et al.  The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. , 1994, The Journal of infectious diseases.

[33]  D. Richman,et al.  A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus. , 1993, The Journal of infectious diseases.

[34]  I. Keet,et al.  Prognostic Value of HIV-1 Syncytium-Inducing Phenotype for Rate of CD4+ Cell Depletion and Progression to AIDS , 1993, Annals of Internal Medicine.

[35]  H. Schuitemaker,et al.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population , 1992, Journal of virology.

[36]  Huisman,et al.  Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex , 1988, Journal of virology.